Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency.

@article{Fasth2007SafetyAE,
  title={Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency.},
  author={Anders L Fasth and Jeanette Nystr{\"o}m},
  journal={Acta paediatrica},
  year={2007},
  volume={96 10},
  pages={1474-8}
}
UNLABELLED The primary objective of this prospective, open-label study was to evaluate the safety and tolerability of home treatment with a 16%, ready-to-use, human normal immunoglobulin solution for subcutaneous administration (SCIg 16%, Subcuvia, Baxter Medical AB, Kista, Sweden) in children with primary immunodeficiency (PI) previously receiving intravenous immunoglobulins (IVIg) treatment. Secondary objectives were to evaluate the efficacy of SCIg 16% through documented bacterial infections… CONTINUE READING

From This Paper

Topics from this paper.
27 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

Similar Papers

Loading similar papers…